• 25427 Citations
  • 63 h-Index
19972019
If you made any changes in Pure these will be visible here soon.

Fingerprint Fingerprint is based on mining the text of the person's scientific documents to create an index of weighted terms, which defines the key subjects of each individual researcher.

  • 60 Similar Profiles
Melanoma Medicine & Life Sciences
Therapeutics Medicine & Life Sciences
Neoplasms Medicine & Life Sciences
Immunotherapy Medicine & Life Sciences
Survival Medicine & Life Sciences
Mutation Medicine & Life Sciences
Italy Medicine & Life Sciences
Safety Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 1997 2019

An open-label, multicentre safety study of vemurafenib in patients with BRAFV600-mutant metastatic melanoma: final analysis and a validated prognostic scoring system

Larkin, J., Brown, M. P., Arance, A. M., Hauschild, A., Queirolo, P., Vecchio, M. D., Ascierto, P. A., Krajsová, I., Schachter, J., Neyns, B., Garbe, C., Sileni, V. C., Mandalà, M., Gogas, H., Espinosa, E., Hospers, G., Lorigan, P., Nyakas, M., Guminski, A., Liszkay, G. & 5 othersRutkowski, P., Miller, W., Donica, M., Makrutzki, M. & Blank, C., Jan 1 2019, In : European Journal of Cancer. 107, p. 175-185 11 p.

Research output: Contribution to journalArticle

Multicenter Studies
Melanoma
Safety
Mutation
PLX4032

The potential of BRAF-associated non-coding RNA as a therapeutic target in melanoma

Fattore, L., Mancini, R., Ascierto, P. A. & Ciliberto, G., Jan 2 2019, In : Expert Opinion on Therapeutic Targets. 23, 1, p. 53-68 16 p.

Research output: Contribution to journalArticle

Adjuvant melanoma therapy with new drugs: should physicians continue to focus on metastatic disease or use it earlier in primary melanoma?

Grob, J. J., Garbe, C., Ascierto, P., Larkin, J., Dummer, R. & Schadendorf, D., Dec 1 2018, In : The Lancet Oncology. 19, 12, p. e720-e725

Research output: Contribution to journalReview article

Melanoma
Physicians
Secondary Prevention
Pharmaceutical Preparations
Therapeutics
64 Citations

Adjuvant pembrolizumab versus placebo in resected stage III melanoma

Eggermont, A. M. M., Blank, C. U., Mandala, M., Long, G. V., Atkinson, V., Dalle, S., Haydon, A., Lichinitser, M., Khattak, A., Carlino, M. S., Sandhu, S., Larkin, J., Puig, S., Ascierto, P. A., Rutkowski, P., Schadendorf, D., Koornstra, R., Hernandez-Aya, L., Maio, M., Van Den Eertwegh, A. J. M. & 9 othersGrob, J. J., Gutzmer, R., Jamal, R., Lorigan, P., Ibrahim, N., Marreaud, S., Van Akkooi, A. C. J., Suciu, S. & Robert, C., May 10 2018, In : New England Journal of Medicine. 378, 19, p. 1789-1801 13 p.

Research output: Contribution to journalArticle

Melanoma
Placebos
Recurrence
Survival
Poisons
16 Citations

Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial

Maio, M., Lewis, K., Demidov, L., Mandalà, M., Bondarenko, I., Ascierto, P., Herbert, C., Mackiewicz, A., Rutkowski, P., Guminski, A., Goodman, G. R., Simmons, B., Ye, C., Yan, Y., Schadendorf, D., Cinat, G., Fein, L. E., Brown, M., Guminski, A., Haydon, A. & 24 othersKhattak, A., McNeil, C., Parente, P., Power, J., Roberts-Thomson, R., Sandhu, S., Underhill, C., Varma, S., Berger, T., Awada, A., Blockx, N., Buyse, V., Mebis, J., Franke, F. A., Jobim de Azevedo, S., Silva Lazaretti, N., Jamal, R., Mihalcioiu, C., Petrella, T., Savage, K., Bianchi, L., Chiarion Sileni, V., Cognetti, F. & Gianni, L., Apr 1 2018, In : The Lancet Oncology. 19, 4, p. 510-520 11 p.

Research output: Contribution to journalArticle

Melanoma
Placebos
Mutation
Disease-Free Survival
Keratoacanthoma